NCT04843943UnknownPhase 1
An Exploratory Study of Sintilimab in Combination With Bevacizumab Biosimilar in Patients With Potentially Resectable Intermediate HCC
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Sponsor
- Fudan University
- Enrollment
- 30
- Primary Endpoint
- Events Free Survival (EFS) Assessed by RECIST1.1
Study Overview
Brief Summary
This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Able to provide informed consent and willing to sign an approved consent form
- •Age 18-75, male and female
- •Potentially resectable Intermediate (CNLC-IIa and IIb) HCC with diagnosis confirmed by histology/cytology or clinically
- •No prior therapy for HCC
- •Child-Pugh: A
- •ECOG PS: 0-1
- •Expected survival ≥6 months
- •Measurable disease per RECIST1.1
- •Major organ functions meet the following requirements:
- •no blood transfusion, no use of hematopoietic stimulators (including g-csf, gm-csf, EPO and TPO) and infusion of human albumin preparations within 14 days prior to screening: neutrophil absolute count ≥1.0×10^9/L;Platelet count ≥ 75×10^9/L;Hemoglobin ≥ 9 g/dL;Serum albumin ≥ 2.8 g/dL;Total serum bilirubin ≤2.0× upper limit of normal range (ULN);Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN;Serum creatinine (Cr) ≤1.5×ULN or Cr clearance ≥30 mL/min (calculated by Cockcroft-Gault formula);International standardized ratio (INR) ≤1.5×ULN;
- •Women of childbearing age must undergo a blood pregnancy test within the first 3 days of randomization with negative results and agree to use a reliable and effective method of contraception during the trial and within 120 days of the last trial drug administration. Male patients whose partners are women of childbearing age must agree to use a reliable and effective method of contraception during the trial and within 120 days of the last trial drug administration.
Exclusion Criteria
- •known as cholangiocarcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, and hepatic fibrolamellar carcinoma.
- •History of organ transplantation or hepatic encephalopathy
- •Tumor accumulation range exceeds 70% of liver volume
- •Pleural fluid, ascites, and pericardial effusion with clinical symptoms requiring drainage
- •Any history of kidney disease or nephrotic syndrome
- •History of gastrointestinal (GI) perforation and/or fistula in the past 6 months;Severe (G3) varicose veins are known to be present on endoscopy within 3 months before the first dose ; history of thrombosis, bleeding diathesis, coagulopathy or significant vascular disease
- •Prior life-threatening blood loss or grade 3/4 gastrointestinal bleeding requiring blood infusion, endoscopic or surgical intervention within 3 months
- •Arterial and venous thromboembolic events in the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism history.
- •Severe bleeding tendency or coagulopathy, or are receiving thrombolytic therapy
- •Long-term use of vitamin K antagonists (such as warfarin) or low-dose low-molecular-weight heparin (such as enoxaparin 40 mg/day) or heparin
- •Uncontrollable hypertension, systolic blood pressure> 140 mmHg or diastolic blood pressure> 90 mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy
- •Symptomatic congestive heart failure (New York Heart Association Grade II-IV), symptomatic or poorly controlled arrhythmia, history of congenital long QT syndrome or QTc> 500ms corrected during screening
- •History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months of initiation of study treatment
- •Had major surgical procedure within 4 weeks of initiation of study treatment
- •Past and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severely impaired lung function and other lung diseases
- •Had acute or chronic active hepatitis B or C infection. Hepatitis C virus (HCV) RNA>103 copies/ml; hepatitis B surface antigen (HbsAg) and anti-HCV antibody are positive at the same time; hepatitis B virus (HBV) DNA positive but has received antiviral treatment is allowed.
- •Had active tuberculosis (TB)
- •Had human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive), known syphilis infection
- •Had severe infections that are active or poorly clinically controlled.
- •Had active autoimmune disease
- •Have used immunosuppressive drugs within 4 weeks before the first dose
- •Received live attenuated vaccines within 4 weeks before the first dose or plan to receive live attenuated vaccines during the study period
- •Received Chinese medicine with anti-tumor indications, or received drugs with immunomodulatory effect within 2 weeks before the first administration
- •Received any anti-PD-1 antibody, anti-PD-L1/L2 antibody, anti-CTLA4 antibody, or other immunotherapy
- •Allergic to Sintilizumab, Bevacizumab preparations and excipients, or had severe allergic reactions to other monoclonal antibodies in the past
- •Received treatment from other clinical trials within 4 weeks before the first dose
- •Female patients who are pregnant or breastfeeding
Arms & Interventions
Sintilimab+Bevacizumab
Experimental
Intervention: Sintilimab (Drug)
Sintilimab+Bevacizumab
Experimental
Intervention: Bevacizumab Biosimilar (Drug)
Outcomes
Primary Outcomes
Events Free Survival (EFS) Assessed by RECIST1.1
Time Frame: Up to 2 years
Defined as the time from enrollment to disease progression, recurrence or death (whichever occurs first)
Adverse Events (AEs)
Time Frame: Up to 2 years
Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0; Surgical safety including Intraoperative blood loss，PHLF assessed by ISGLS（2012），Postoperative complications evaluated by modified Clavien-Dindo system
Secondary Outcomes
- Pathological response rate(Up to 2 years)
- resection rate (R0 resection rate)(Up to 2 years)
- Recurrence-free survival (RFS) of patients who accepted surgery(Up to 2 years)
- Progression free survival (PFS) assessed by RECIST1.1 of patients who didn't accept surgery(Up to 2 years)
- Overall survival (OS) of the patients who accepted surgery(Up to 2 years)
- Overall survival (OS)(Up to 2 years)
- Objective response rate (ORR) assessed by RECIST1.1(Up to 2 years)
- Overall survival (OS) of the patients who didn't accepted surgery(Up to 2 years)
Investigators
Jia Fan
Director of hospital
Fudan University
Similar Trials
Unknown
Phase 2
Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung CancerBrain MetastasesNon Small Cell Lung CancerSintilimabBevacizumabNCT04213170Sun Yat-sen University60
Recruiting
Not Applicable
A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal CancerColorectal CancerNCT05544812Xijing Hospital10
Recruiting
Phase 2
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMMalignant Peritoneal Mesothelioma, AdvancedNCT06543069Cancer Institute and Hospital, Chinese Academy of Medical Sciences28
Active, not recruiting
Phase 2
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT05010434Sun Yat-sen University46
Recruiting
Phase 2
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)Esophageal Squamous Cell Carcinoma (ESCC)NCT06709417Shanghai Chest Hospital52